Focus on Pathways: Inhibition of the BCL-2 Pathway in Hematologic Malignancies

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.